<p>Oruka Therapeutics, Inc.（NASDAQ:ORKA - 获取免费报告）的股票在覆盖该股票的十位分析师中被赋予了 “适度买入” 的平均推荐，MarketBeat.com 报道称。一位研究分析师对该股票给予了卖出推荐，八位分析师给予了买入推荐，还有一位分析师对该公司发出了强烈买入推荐。在过去一年中，覆盖该股票的经纪商的平均一年目标价为 50.6667 美元。</p>
<p>获取 <strong>Oruka Therapeutics</strong> 的提醒：</p>
<p>ORKA 已成为多份研究分析师报告的主题。BTIG Research 在 1 月 12 日的报告中将 Oruka Therapeutics 的目标价从 63.00 美元上调至 73.00 美元，并给予该公司 “买入” 评级。Weiss Ratings 在 1 月 22 日的研究报告中重申了对 Oruka Therapeutics 股票的 “卖出（d-）” 评级。HC Wainwright 在 10 月 27 日的研究报告中将 Oruka Therapeutics 股票的目标价从 45.00 美元下调至 40.00 美元，并对该股票给予了 “买入” 评级。Wedbush 在 1 月 13 日的研究报告中将 Oruka Therapeutics 股票的目标价从 42.00 美元上调至 45.00 美元，并给予该公司 “跑赢大盘” 评级。最后，Jefferies Financial Group 在 11 月 13 日的报告中开始覆盖 Oruka Therapeutics 股票。他们对该股票给予了 “买入” 评级，并设定了 45.00 美元的目标价。</p>
<p><strong>查看我们最新的 ORKA 股票报告</strong></p>
<h2>内部活动</h2>
<p>在相关消息中，内部人士 Joana Goncalves 于 1 月 15 日星期四出售了 7,000 股公司的股票。该股票以平均价格 31.81 美元出售，总交易额为 222,670.00 美元。交易完成后，该内部人士在公司持有 1,518 股，价值 48,287.58 美元。此次交易使其持股减少了 82.18%。该交易已在向 SEC 提交的文件中披露，文件可通过此超链接获取。公司内部人士持有公司股票的 24.69%。</p>
<h2>对 Oruka Therapeutics 的对冲基金看法</h2>
<p>机构投资者最近调整了对该公司的持股。Legal &amp; General Group Plc 在第二季度购买了 Oruka Therapeutics 的新股份，价值约 28,000 美元。Ameritas Investment Partners Inc. 在第二季度购买了 Oruka Therapeutics 的新股份，价值约 31,000 美元。BNP Paribas Financial Markets 在第二季度将其在 Oruka Therapeutics 的持股增加了 464.0%。BNP Paribas Financial Markets 现在拥有 2,803 股公司股票，价值 31,000 美元，此前在该期间内又购买了 2,306 股。PNC Financial Services Group Inc. 在第三季度购买了 Oruka Therapeutics 的新股份，价值约 39,000 美元。最后，Russell Investments Group Ltd. 在第三季度收购了 Oruka Therapeutics 的新股份，价值约 43,000 美元。机构投资者持有公司股票的 56.44%。</p>
<h2>Oruka Therapeutics 价格表现</h2>
<p>ORKA 股票在周五开盘价为 34.23 美元。该公司的 50 日移动平均线为 30.93 美元，200 日移动平均线为 23.51 美元。该公司的市值为 16.6 亿美元，市盈率为 -18.02，贝塔值为 -0.39。Oruka Therapeutics 的一年低点为 5.49 美元，一年高点为 36.51 美元。</p>
<p>Oruka Therapeutics（NASDAQ:ORKA - 获取免费报告）最近在 11 月 12 日星期三发布了季度财报。该公司报告季度每股收益为（0.55）美元，超出分析师共识预期的（0.56）美元 0.01 美元。平均而言，卖方分析师预计 Oruka Therapeutics 本年度将发布 -3.41 美元的每股收益。</p>
<h2>Oruka Therapeutics 公司简介</h2>
<p>（获取免费报告）</p>
<p>Oruka Therapeutics, Inc 是一家临床阶段的生物制药公司，专注于开发用于肿瘤学的新型肽类治疗。该公司的专有钉合肽平台旨在选择性地破坏驱动肿瘤生长和免疫逃逸的细胞内蛋白质 - 蛋白质相互作用。通过将生物制剂的特异性与小分子的细胞渗透性相结合，Oruka 旨在针对历史上被认为 “不可药物化” 的癌症通路。</p>
<p>该公司的主要候选药物 ONCT-01 目前正在针对晚期实体瘤患者进行 1 期临床试验，评估其安全性、耐受性和初步疗效。</p>
<h2>推荐故事</h2>
<ul>
<li>我们更看好的五只股票超过 Oruka Therapeutics</li>
<li>请勿删除，立即阅读</li>
<li>新法律：国会批准数字美元的设立？</li>
<li>用这 4 个简单步骤 “防止美联储影响” 您的银行账户</li>
<li>一项价值数万亿的美国 “出生权” 索赔 - 静悄悄地激活</li>
<li>崩盘已经开始（大多数人只是不知道而已）</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T1JLQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T1JLQQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Oruka Therapeutics 吗？</h2>
<p>在考虑 Oruka Therapeutics 之前，你会想听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前立即购买……而 Oruka Therapeutics 并不在名单上。</p>
<p>虽然 Oruka Therapeutics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

<p>Oruka Therapeutics, Inc.（纳斯达克代码：ORKA）获得了十位分析师的平均评级为 “适度买入”。该股票有一项卖出建议、八项买入建议和一项强烈买入建议。平均目标价格为 50.67 美元。最近的分析师报告包括 BTIG 将目标价格上调至 73.00 美元，以及 HC Wainwright 将其下调至 40.00 美元。内部人士 Joana Goncalves 以 31.81 美元的价格出售了 7,000 股。机构投资者持有该公司 56.44% 的股份。ORKA 开盘价为 34.23 美元，市值为 16.6 亿美元，市盈率为-18.02。该公司专注于肿瘤学的基于肽的疗法，其主要候选药物正在进行第一阶段临床试验</p>

<p>Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report) have been assigned an average recommendation of &#34;Moderate Buy&#34; from the ten analysts that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, eight have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year target price among brokers that have covered the stock in the last year is $50.6667.</p>
<div class="lb-trans"><p>Oruka Therapeutics, Inc.（NASDAQ:ORKA - 获取免费报告）的股票在覆盖该股票的十位分析师中被赋予了 “适度买入” 的平均推荐，MarketBeat.com 报道称。一位研究分析师对该股票给予了卖出推荐，八位分析师给予了买入推荐，还有一位分析师对该公司发出了强烈买入推荐。在过去一年中，覆盖该股票的经纪商的平均一年目标价为 50.6667 美元。</p>
</div><p>Get <strong>Oruka Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Oruka Therapeutics</strong> 的提醒：</p>
</div><p>ORKA has been the subject of a number of research analyst reports. BTIG Research boosted their price target on Oruka Therapeutics from $63.00 to $73.00 and gave the company a &#34;buy&#34; rating in a report on Monday, January 12th. Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Oruka Therapeutics in a research note on Thursday, January 22nd. HC Wainwright reduced their price target on shares of Oruka Therapeutics from $45.00 to $40.00 and set a &#34;buy&#34; rating on the stock in a research report on Monday, October 27th. Wedbush boosted their price objective on shares of Oruka Therapeutics from $42.00 to $45.00 and gave the company an &#34;outperform&#34; rating in a research report on Tuesday, January 13th. Finally, Jefferies Financial Group started coverage on shares of Oruka Therapeutics in a report on Thursday, November 13th. They issued a &#34;buy&#34; rating and a $45.00 target price on the stock.</p>
<div class="lb-trans"><p>ORKA 已成为多份研究分析师报告的主题。BTIG Research 在 1 月 12 日的报告中将 Oruka Therapeutics 的目标价从 63.00 美元上调至 73.00 美元，并给予该公司 “买入” 评级。Weiss Ratings 在 1 月 22 日的研究报告中重申了对 Oruka Therapeutics 股票的 “卖出（d-）” 评级。HC Wainwright 在 10 月 27 日的研究报告中将 Oruka Therapeutics 股票的目标价从 45.00 美元下调至 40.00 美元，并对该股票给予了 “买入” 评级。Wedbush 在 1 月 13 日的研究报告中将 Oruka Therapeutics 股票的目标价从 42.00 美元上调至 45.00 美元，并给予该公司 “跑赢大盘” 评级。最后，Jefferies Financial Group 在 11 月 13 日的报告中开始覆盖 Oruka Therapeutics 股票。他们对该股票给予了 “买入” 评级，并设定了 45.00 美元的目标价。</p>
</div><p><strong>Check Out Our Latest Stock Report on ORKA</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 ORKA 股票报告</strong></p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部活动</h2>
</div><p>In related news, insider Joana Goncalves sold 7,000 shares of the business's stock in a transaction that occurred on Thursday, January 15th. The stock was sold at an average price of $31.81, for a total transaction of $222,670.00. Following the completion of the transaction, the insider owned 1,518 shares in the company, valued at $48,287.58. The trade was a 82.18% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 24.69% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，内部人士 Joana Goncalves 于 1 月 15 日星期四出售了 7,000 股公司的股票。该股票以平均价格 31.81 美元出售，总交易额为 222,670.00 美元。交易完成后，该内部人士在公司持有 1,518 股，价值 48,287.58 美元。此次交易使其持股减少了 82.18%。该交易已在向 SEC 提交的文件中披露，文件可通过此超链接获取。公司内部人士持有公司股票的 24.69%。</p>
</div><h2>Hedge Funds Weigh In On Oruka Therapeutics</h2>
<div class="lb-trans"><h2>对 Oruka Therapeutics 的对冲基金看法</h2>
</div><p>Institutional investors have recently modified their holdings of the company. Legal &amp; General Group Plc bought a new stake in Oruka Therapeutics in the 2nd quarter valued at about $28,000. Ameritas Investment Partners Inc. bought a new stake in shares of Oruka Therapeutics during the second quarter valued at approximately $31,000. BNP Paribas Financial Markets boosted its position in shares of Oruka Therapeutics by 464.0% during the second quarter. BNP Paribas Financial Markets now owns 2,803 shares of the company's stock worth $31,000 after buying an additional 2,306 shares during the period. PNC Financial Services Group Inc. bought a new position in Oruka Therapeutics in the 3rd quarter worth approximately $39,000. Finally, Russell Investments Group Ltd. acquired a new stake in Oruka Therapeutics in the 3rd quarter valued at approximately $43,000. Institutional investors own 56.44% of the company's stock.</p>
<div class="lb-trans"><p>机构投资者最近调整了对该公司的持股。Legal &amp; General Group Plc 在第二季度购买了 Oruka Therapeutics 的新股份，价值约 28,000 美元。Ameritas Investment Partners Inc. 在第二季度购买了 Oruka Therapeutics 的新股份，价值约 31,000 美元。BNP Paribas Financial Markets 在第二季度将其在 Oruka Therapeutics 的持股增加了 464.0%。BNP Paribas Financial Markets 现在拥有 2,803 股公司股票，价值 31,000 美元，此前在该期间内又购买了 2,306 股。PNC Financial Services Group Inc. 在第三季度购买了 Oruka Therapeutics 的新股份，价值约 39,000 美元。最后，Russell Investments Group Ltd. 在第三季度收购了 Oruka Therapeutics 的新股份，价值约 43,000 美元。机构投资者持有公司股票的 56.44%。</p>
</div><h2>Oruka Therapeutics Price Performance</h2>
<div class="lb-trans"><h2>Oruka Therapeutics 价格表现</h2>
</div><p>Shares of ORKA stock opened at $34.23 on Friday. The firm has a fifty day moving average of $30.93 and a two-hundred day moving average of $23.51. The firm has a market cap of $1.66 billion, a P/E ratio of -18.02 and a beta of -0.39. Oruka Therapeutics has a 1-year low of $5.49 and a 1-year high of $36.51.</p>
<div class="lb-trans"><p>ORKA 股票在周五开盘价为 34.23 美元。该公司的 50 日移动平均线为 30.93 美元，200 日移动平均线为 23.51 美元。该公司的市值为 16.6 亿美元，市盈率为 -18.02，贝塔值为 -0.39。Oruka Therapeutics 的一年低点为 5.49 美元，一年高点为 36.51 美元。</p>
</div><p>Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($0.55) EPS for the quarter, topping analysts' consensus estimates of ($0.56) by $0.01. On average, sell-side analysts expect that Oruka Therapeutics will post -3.41 EPS for the current year.</p>
<div class="lb-trans"><p>Oruka Therapeutics（NASDAQ:ORKA - 获取免费报告）最近在 11 月 12 日星期三发布了季度财报。该公司报告季度每股收益为（0.55）美元，超出分析师共识预期的（0.56）美元 0.01 美元。平均而言，卖方分析师预计 Oruka Therapeutics 本年度将发布 -3.41 美元的每股收益。</p>
</div><h2>Oruka Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Oruka Therapeutics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company's proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”</p>
<div class="lb-trans"><p>Oruka Therapeutics, Inc 是一家临床阶段的生物制药公司，专注于开发用于肿瘤学的新型肽类治疗。该公司的专有钉合肽平台旨在选择性地破坏驱动肿瘤生长和免疫逃逸的细胞内蛋白质 - 蛋白质相互作用。通过将生物制剂的特异性与小分子的细胞渗透性相结合，Oruka 旨在针对历史上被认为 “不可药物化” 的癌症通路。</p>
</div><p>The company's lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.</p>
<div class="lb-trans"><p>该公司的主要候选药物 ONCT-01 目前正在针对晚期实体瘤患者进行 1 期临床试验，评估其安全性、耐受性和初步疗效。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Oruka Therapeutics</li>
<li>Do not delete, read immediately</li>
<li>NEW LAW: Congress Approves Setup For Digital Dollar?</li>
<li>“Fed Proof” Your Bank Account with THESE 4 Simple Steps</li>
<li>A U.S. “birthright” claim worth trillions - activated quietly</li>
<li>The Crash Has Already Started (Most Just Don’t See It Yet)</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过 Oruka Therapeutics</li>
<li>请勿删除，立即阅读</li>
<li>新法律：国会批准数字美元的设立？</li>
<li>用这 4 个简单步骤 “防止美联储影响” 您的银行账户</li>
<li>一项价值数万亿的美国 “出生权” 索赔 - 静悄悄地激活</li>
<li>崩盘已经开始（大多数人只是不知道而已）</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T1JLQQ" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=ORKA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Oruka Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Oruka Therapeutics 吗？</h2>
</div><p>Before you consider Oruka Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Oruka Therapeutics 之前，你会想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oruka Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前立即购买……而 Oruka Therapeutics 并不在名单上。</p>
</div><p>While Oruka Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Oruka Therapeutics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Oruka Therapeutics, Inc. (NASDAQ:ORKA) Given Average Rating of "Moderate Buy" by Analysts

Market Beat

美国制药 ETF - iShares

标普全球医疗股指数 ETF - iShares

Invesco Nasdaq Biotechnology ETF

医疗业 ETF - SPDR

纽交所高增长板生物技术指数 ETF - First Trust

Oruka Therapeutics

医疗业 ETF - Vanguard

标普生物技术 ETF - SPDR

纳斯达克生物科技指数 ETF - iShares Nasdaq

2 倍做多纳斯达克生物技术 ETF - ProShares

动态生物技术与基因组 ETF - Invesco

生物科技 ETF - VanEck Vectors

医药突破 ETF - ALPS

Oruka Therapeutics, Inc. (NASDAQ:ORKA) 被分析师平均评级为 “适度买入”